• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于主动脉瓣介入的栓塞转向装置。

An embolic deflection device for aortic valve interventions.

机构信息

Department of Cardiology, St. Paul's Hospital, Vancouver, British Columbia, Canada.

出版信息

JACC Cardiovasc Interv. 2010 Nov;3(11):1133-8. doi: 10.1016/j.jcin.2010.05.022.

DOI:10.1016/j.jcin.2010.05.022
PMID:21087748
Abstract

OBJECTIVES

We describe initial human experience with a novel cerebral embolic protection device.

BACKGROUND

Cerebral emboli are the major cause of procedural stroke during percutaneous aortic valve interventions.

METHODS

With right radial artery access, the embolic protection device is advanced into the aortic arch. Once deployed a porous membrane shields the brachiocephalic trunk and the left carotid artery deflecting emboli away from the cerebral circulation. Embolic material is not contained or removed by the device. The device was used in 4 patients (mean age 90 years) with severe aortic stenosis undergoing aortic balloon valvuloplasty (n = 1) or transcatheter aortic valve implantation (n = 3).

RESULTS

Correct placement of the embolic protection device was achieved without difficulty in all patients. Continuous brachiocephalic and aortic pressure monitoring documented equal pressures without evidence of obstruction to cerebral perfusion. Additional procedural time due to the use of the device was 13 min (interquartile range: 12 to 16 min). There were no procedural complications. Pre-discharge cerebral magnetic resonance imaging found no new defects in any of 3 patients undergoing transcatheter aortic valve implantation and a new 5-mm acute cortical infarct in 1 asymptomatic patient after balloon valvuloplasty alone. No patient developed new neurological symptoms or clinical findings of stroke.

CONCLUSIONS

Embolic protection during transcatheter aortic valve intervention seems feasible and might have the potential to reduce the risk of cerebral embolism and stroke.

摘要

目的

我们描述一种新型脑保护装置的初步人体应用经验。

背景

在经皮主动脉瓣介入治疗过程中,脑栓塞是操作相关性卒中的主要原因。

方法

通过右侧桡动脉入路,将栓塞保护装置推进至主动脉弓。装置展开后,多孔膜可保护头臂干和左侧颈动脉,使栓塞物远离脑循环。该装置不会容纳或移除栓塞物。该装置应用于 4 名(平均年龄 90 岁)严重主动脉瓣狭窄患者,其中 1 名接受主动脉球囊瓣膜成形术(n = 1),3 名接受经导管主动脉瓣植入术(n = 3)。

结果

所有患者均能顺利放置栓塞保护装置,无困难。连续的头臂干和主动脉压力监测显示压力相等,无脑灌注受阻的证据。由于使用该装置,额外的手术时间为 13 分钟(四分位间距:12 至 16 分钟)。无手术并发症。在接受经导管主动脉瓣植入术的 3 名患者中,出院前的脑磁共振成像均未发现新的缺损,在仅接受球囊瓣膜成形术的 1 名无症状患者中发现 1 个新的 5 毫米急性皮质梗死。无患者出现新的神经症状或卒中的临床发现。

结论

在经导管主动脉瓣介入治疗过程中进行栓塞保护似乎是可行的,并且有可能降低脑栓塞和卒中的风险。

相似文献

1
An embolic deflection device for aortic valve interventions.一种用于主动脉瓣介入的栓塞转向装置。
JACC Cardiovasc Interv. 2010 Nov;3(11):1133-8. doi: 10.1016/j.jcin.2010.05.022.
2
First-in-man experience with a new embolic deflection device in transcatheter aortic valve interventions.经导管主动脉瓣介入治疗中新型栓塞转向装置的首例人体应用经验。
EuroIntervention. 2012 May 15;8(1):51-6. doi: 10.4244/EIJV8I1A9.
3
First-in-man use of a novel embolic protection device for patients undergoing transcatheter aortic valve implantation.首例新型栓塞保护装置在经导管主动脉瓣植入术中的应用。
EuroIntervention. 2012 May 15;8(1):43-50. doi: 10.4244/EIJV8I1A8.
4
Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement: the PROTAVI-C pilot study.伞形栓塞防护装置预防经导管主动脉瓣置换术患者脑栓塞的可行性和探索性疗效评价:PROTAVI-C 先导研究。
JACC Cardiovasc Interv. 2014 Oct;7(10):1146-55. doi: 10.1016/j.jcin.2014.04.019.
5
Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.新型栓塞转向装置在经导管主动脉瓣置换术中的安全性和性能:来自 DEFLECT I 研究的结果。
EuroIntervention. 2015 May;11(1):75-84. doi: 10.4244/EIJY15M04_01.
6
TriGuard HDH embolic deflection device for cerebral protection during transcatheter aortic valve replacement.用于经导管主动脉瓣置换术中脑保护的TriGuard HDH栓子偏转装置。
Catheter Cardiovasc Interv. 2017 Feb 15;89(3):470-477. doi: 10.1002/ccd.26566. Epub 2016 Apr 28.
7
Front stroke, back stroke: the "emerging" interest of stroke in transcatheter aortic valve implantation.前行程、后行程:经导管主动脉瓣植入术中中风的“新出现”的相关问题
JACC Cardiovasc Interv. 2010 Nov;3(11):1139-40. doi: 10.1016/j.jcin.2010.07.014.
8
Embrella embolic deflection device for cerebral protection during transcatheter aortic valve replacement.用于经导管主动脉瓣置换术期间脑保护的Embrella栓塞偏转装置。
J Thorac Cardiovasc Surg. 2015 Mar;149(3):799-805.e1-2. doi: 10.1016/j.jtcvs.2014.05.097. Epub 2014 Oct 17.
9
Cerebral events and protection during transcatheter aortic valve replacement.经导管主动脉瓣置换术中的脑部事件与保护
Catheter Cardiovasc Interv. 2014 Nov 15;84(6):885-96. doi: 10.1002/ccd.25457. Epub 2014 Mar 4.
10
Embolic cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging.经磁共振成像检测,经心尖主动脉瓣植入术后发生脑栓塞性损伤。
JACC Cardiovasc Interv. 2010 Nov;3(11):1126-32. doi: 10.1016/j.jcin.2010.09.008.

引用本文的文献

1
Cerebral Embolic Protection in TAVI: Friend or Foe.经导管主动脉瓣植入术中的脑栓塞保护:是友还是敌?
Interv Cardiol. 2019 Feb;14(1):22-25. doi: 10.15420/icr.2018.32.2.
2
Cerebral embolic protection devices during transcatheter aortic valve implantation: clinical versus silent embolism.经导管主动脉瓣植入术中的脑栓塞保护装置:临床栓塞与隐匿性栓塞
J Thorac Dis. 2018 Nov;10(Suppl 30):S3604-S3613. doi: 10.21037/jtd.2018.09.62.
3
The Role of Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Replacement.脑栓塞保护装置在经导管主动脉瓣置换术中的作用
Front Cardiovasc Med. 2018 Oct 23;5:150. doi: 10.3389/fcvm.2018.00150. eCollection 2018.
4
Stroke following transcatheter aortic valve implantation. Is neuroprotection justified?经导管主动脉瓣植入术后的中风。神经保护是否合理?
Postepy Kardiol Interwencyjnej. 2013;9(4):376-82. doi: 10.5114/pwki.2013.38868. Epub 2013 Nov 18.
5
Evaluation of embolic deflection device using optical particle tracking.使用光学粒子追踪技术评估栓塞偏转装置。
Proc SPIE Int Soc Opt Eng. 2013 Mar 29;8672:867216-. doi: 10.1117/12.2004319.
6
Almanac 2013: novel non-coronary cardiac interventions.2013 年手册:新型非冠状动脉心脏介入治疗。
Wien Klin Wochenschr. 2013 Dec;125(23-24):766-75. doi: 10.1007/s00508-013-0481-5.
7
Challenges in cardiac device innovation: is neuroimaging an appropriate endpoint? Consensus from the 2013 Yale-UCL Cardiac Device Innovation Summit.心脏设备创新面临的挑战:神经影像学是否为合适的终点?2013 年耶鲁大学-伦敦大学学院心脏设备创新峰会的共识。
BMC Med. 2013 Dec 11;11:257. doi: 10.1186/1741-7015-11-257.
8
Mechanisms and management of TAVR-related complications.经导管主动脉瓣置换术相关并发症的机制与处理。
Nat Rev Cardiol. 2013 Dec;10(12):685-95. doi: 10.1038/nrcardio.2013.156. Epub 2013 Oct 8.
9
Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies.经导管主动脉瓣置换术的当前围手术期抗凝治疗:可否使用比伐卢定?BRAVO 2/3 研究的原理和设计。
J Thromb Thrombolysis. 2013 May;35(4):483-93. doi: 10.1007/s11239-013-0890-3.
10
Incidence, predictors, origin and prevention of early and late neurological events after transcatheter aortic valve implantation (TAVI): a comprehensive review of current data.经导管主动脉瓣植入术(TAVI)后早期和晚期神经系统事件的发生率、预测因素、起源和预防:对当前数据的综合回顾。
J Thromb Thrombolysis. 2013 May;35(4):436-49. doi: 10.1007/s11239-012-0863-y.